Mannkind Announced A New US Patent Covering Clofazimine Inhalation Suspension (MNKD-101), Under Development For Nontuberculous Mycobacterial Lung Disease. The Patent Will Expire On June 8, 2039
Portfolio Pulse from Benzinga Newsdesk
MannKind Corporation has announced a new US patent for its Clofazimine Inhalation Suspension (MNKD-101), which is under development for Nontuberculous Mycobacterial Lung Disease. The patent will expire on June 8, 2039.
October 30, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MannKind's new patent for MNKD-101 could potentially strengthen its product pipeline and provide long-term revenue potential.
The new patent for MNKD-101, which is under development for Nontuberculous Mycobacterial Lung Disease, could potentially strengthen MannKind's product pipeline. This could provide the company with long-term revenue potential, which is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100